Testing uptake among unselected breast cancer patients offered germline BRCA1/2 pathogenic variant testing varied across different subgroups according to patient-related factors, a recent study found. Pretest information was provided by a standardized invitation letter instead of in-person counseling. Predictors of testing uptake were analyzed using multivariate logistic regressions. Researchers found:
- The overall uptake of testing was 67% (539 of 805 patients).
- Low uptake rates were found for patients aged ≥80 years (33%), and patients born outside of Europe (37%).
- In adjusted analysis, age ≥80 years, psychiatric disorders, occupation requiring at least 3 years of university or college education, and breast cancer or ovarian cancer in first-degree or second-degree relatives were independently associated with uptake of BRCA1/2 testing.
- Somatic comorbidity in patients aged <70 years was associated with lower testing uptake.
Nilsson MP, Nilsson ED, Silfverberg B, Borg Å, Loman N. Written pretest information and germline BRCA1/2 pathogenic variant testing in unselected breast cancer patients: Predictors of testing uptake. [Published online ahead of print June 6, 2018]. Genet Med. doi:10.1038/s41436-018-0021-9.
Must Reads in Genetics
Genetic Literacy Awareness in the US Population, Public Health Genomics; ePub 2018 May 31; Krakow, et al
Genetic Testing Uptake in Breast Cancer Patients, Genet Med; ePub 2018 Jun 6; Nilsson, et al
Genetic Testing for Hypertrophic Cardiomyopathy, Genet Med; ePub 2018 Jun 6; Mazzarotto, et al
Returning Negative Genomic Screening Results, Genet Med; ePub 2018 Jun 6; Butterfield, et al
Distinguishing Among Cardiac Genomic Variants, Circ Genom Precis Med; 2018 Jun; Hellwig, et al